Milvexian is an investigational, oral anticoagulant that functions as a factor XIa (FXIa) inhibitor, designed to prevent blood clots without increasing bleeding risk. It is currently in Phase 3 Librexia trials for reducing thromboembolic events, including ischemic stroke, acute coronary syndrome, and atrial fibrillation. It is grouped under the following drug class(es): Antithrombotic agents. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include GLXC-23230 and GTPL11754. Its PubChem CID is 118277544.
Milvexian
| CAS No | 1802425-99-5 |
|---|---|
| Molecular Formula | C28H23Cl2F2N9O2 |
| Molecular Weight | 626.4 g/mol |
| Synonyms | (9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Milvexian is an investigational, oral anticoagulant that functions as a factor XIa (FXIa) inhibitor, designed to prevent blood clots without increasing bleeding risk.
The listed CAS number is 1802425-99-5.
The listed molecular formula is C28H23Cl2F2N9O2.
The listed molecular weight is 626.4 g/mol.
(9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one.
The source lists GLXC-23230 and GTPL11754.